NCT00089895 - EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) | Biotech Hunter

Enrollment

9,406

Participants

Timeline

Start Date

November 1, 2004

Primary Completion Date

November 1, 2008

Study Completion Date

November 1, 2008

Conditions

Myocardial IschemiaAcute Coronary Syndrome

Interventions

DRUG

Eptifibatide (Integrilin)

intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG \[coronary artery bypass graft\]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.

DRUG

Placebo

intravenous; delivery to match eptifibatide to maintain blind